Teva’s TEV ‘408 meets Phase 2a celiac primary endpoint
A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. Drug was well-tolerated.